Levosimendan and renal function

Česká verzia

Authors: F. Málek; P. Ošťádal; A. Krüger; D. Vondráková; J. Matoušková; P. Neužil
Authors place of work: Kardiovaskulární centrum ; Nemocnice Na Homolce, Praha ; Ambulance srdečního selhání a hypertenze
Published in the journal: Kardiol Rev Int Med 2013, 15(3): 178-180
Category:

Summary

Decreased renal function is usually observed in patients with heart failure, the impaired kidney functions have a negative impact on the outcome and renal dysfunction is a limiting factor for the effect of optimal medical therapy. A short‑term renoprotective effect of Levosimendan was shown in hemodynamic studies. Other studies confirmed that the positive effect of Levosimendan on the kidney function is long‑term. This effect is explained by several mechanisms of action; besides redistribution of renal blood flow, Levosimendan also has an anti‑inflammatory effect.

Keywords:
heart failure – Levosimendan – renal function

Zdroje

1. Endoh M. Mechanisms of action of novel cardiotonic agents. J Cardiovasc Pharmacol 2002; 40: 323– 338.

2. Málek F, Ignaszweski A. Nové léky pro terapii pokročilého srdečního selhání. Cor Vasa 2004; 45: 221– 225.

3. Špinar J, Vítovec J. Intravenózní léčba akutního srdečního selhání. Vnitř Lék 2007; 53: 412– 419.

4. Thackray S, Colleta A, Jones P et al. Clinical trials update: Highlights of the scientific sessions of heart failure 2001. CONTAK‑ CD, CHRISTMAS, OPTIME‑ CHF. Eur J Heart Failure 2001; 3: 491– 494.

5. Cuffe MS, Califf RM, Adams KF Jr et al. The Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME‑ CHF) Investigators. Short‑term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002: 287: 1541– 1547.

6. Follath F, Cleland JG, Just H et al. Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low‑ output heart failure (the LIDO study): a randomised double‑blind trial. Lancet 2002; 360: 196– 202.

7. McAlister FA, Ezekowitz J, Tonelli M et al. Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study. Circulation 2004, 109:1004– 1009.

8. Bock JS, Gottlieb SS. Cardiorenal Syndrome – New Perspectives. Circulation 2010; 121: 2592– 2600.

9. Ronco C, House AA, Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med 2008; 34: 957– 962.

10. Hillege HL, Girbes AR, de Kam PJ et al. Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203– 210.

11. Heywood JT, Fonarow GC, Costanzo MR et al. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007; 13: 422– 430.

12. Damman K, Navis G, Voors AA et al. Worsening renal function and prognosis in heart failure: systematic review and meta‑analysis. J Card Fail 2007; 13: 599– 608.

13. Cleland JG, McGowan J. Levosimendan: a new era for inodilator therapy for heart failure? Curr Opin Cardiol 2002; 17: 257– 265.

14. Nicklas JM, Monsur MW, Pagel PS et al. Effects of intravenous levosimendan on plasma neurohormone levels in patients with heart failure: relation to hemodynamic response. Am J Cardiol 1999; 83: 12(I)– 15(I).

15. Sundberg S, Antila S, Scheinin H et al. Integrated pharmacokinetics and pharmacodynamics of the novel calcium sensitizer levosimendan. Int J Clin Pharmacol Ther 1998; 36: 629– 635.

16. Nieminen MS, Akkila J, Hasenfuss G et al. Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. JACC 2000; 36: 1903– 1912.

17. Slawsky MT, Colucci WS, Gottlieb SS et al. Acute hemodynamic and clinical effects of levosimendan in patients with severe heart failure. Circulation 2000; 102: 2222– 2227.

18. Kivikko M, Lehtonen L, Colucci WS. Sustained hemodynamic effects of intravenous levosimendan. Circulation 2003; 107: 81– 86.

19. Zemljic G, Bunc M, Yazdanbakhsh AP et al. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. J Card Fail 2007; 13: 417– 421.

20. Yilmaz MB, Yalta K, Yontar C et al. Levosimendan improves renal function in patiens with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther 2007; 21: 431– 435.

21. Pagel PS, Hettrick DA, Warltier DC. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol 1996; 119: 609– 615.

22. Zager RA, Johnson AC, Lund S et al. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol 2006; 290: F1453– F1462.

23. Damman K, Navis G, Smilde TD et al. Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007; 9: 872– 878.

24. Parissis JT, Adamopoulos S, Antoniades C et al. Effects of levosimendan on circulating pro‑inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol 2004; 93: 1309– 1312.